{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:20:17Z","timestamp":1781950817788,"version":"3.54.5"},"reference-count":67,"publisher":"Georg Thieme Verlag KG","issue":"09","funder":[{"name":"Austrian Science Fund","award":["SFB54-P04"],"award-info":[{"award-number":["SFB54-P04"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003von Willebrand factor (VWF) is crucial for arterial thrombosis and its plasma levels are increased in acute coronary syndromes (ACSs). The effects of conventional platelet inhibitors are compromised by elevated VWF under high shear rates. BT200 is a third-generation aptamer that binds and inhibits the A1 domain of human VWF. This article aims to study whether VWF is a predictor of mortality in ACS patients under potent P2Y12 blocker therapy and to examine the effects of a VWF inhibiting aptamer BT200 and its concentrations required to inhibit VWF in plasma samples of patients with ACS.<\/jats:p><jats:p>\n          Methods\u2003VWF activity was measured in 320 patients with ACS, and concentration effect curves of BT200 were established in plasma pools containing different VWF concentrations.<\/jats:p><jats:p>\n          Results\u2003Median VWF activity in patients was 170% (interquartile range % confidence interval [CI]: 85\u2013255) and 44% of patients had elevated (&gt; 180%) VWF activity. Plasma levels of VWF activity predicted 1-year (hazard ratio [HR]: 2.68; 95% CI: 1.14\u20136.31; p\u2009&lt;\u20090.024) and long-term (HR: 2.59; 95% CI: 1.10\u20136.09) mortality despite treatment with potent platelet inhibitors (dual-antiplatelet therapy with aspirin and prasugrel or ticagrelor). Although half-maximal concentrations were 0.1 to 0.2 \u00b5g\/mL irrespective of baseline VWF levels, increasing concentrations (0.42\u20132.13 \u00b5g\/mL) of BT200 were needed to lower VWF activity to\u2009&lt;\u200920% of normal in plasma pools containing increasing VWF activity (p\u2009&lt;\u20090.001).<\/jats:p><jats:p>\n          Conclusion\u2003VWF is a predictor of all-cause mortality in ACS patients under contemporary potent P2Y12 inhibitor therapy. BT200 effectively inhibited VWF activity in a target concentration-dependent manner.<\/jats:p>","DOI":"10.1055\/s-0040-1713888","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T22:48:30Z","timestamp":1595026110000},"page":"1282-1290","source":"Crossref","is-referenced-by-count":13,"title":["von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo"],"prefix":"10.1055","volume":"120","author":[{"given":"Katarina D.","family":"Kovacevic","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Guardian Therapeutics, Lexington, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Guardian Therapeutics, Lexington, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max-Paul","family":"Winter","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurel","family":"Toma","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hengstenberg","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Kubica","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria"},{"name":"Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/01.ATV.17.5.919","article-title":"Relative involvement of GPIb\/IX-vWF axis and GPIIb\/IIIa in thrombus growth at high shear rates in the guinea pig","volume":"17","author":"P Andr\u00e9","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0049-3848(00)00326-1","article-title":"Enhanced shear-induced von Willebrand factor binding to platelets in acute myocardial infarction","volume":"100","author":"M Li","year":"2000","journal-title":"Thromb Res"},{"issue":"09","key":"ref3","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood-2005-02-0618","article-title":"Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress","volume":"107","author":"A J Reininger","year":"2006","journal-title":"Blood"},{"issue":"S 01","key":"ref4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.thromres.2007.03.011","article-title":"The role of von Willebrand factor in thrombus formation","volume":"120","author":"Z M Ruggeri","year":"2007","journal-title":"Thromb Res"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1096\/fasebj.7.2.8440408","article-title":"von Willebrand factor","volume":"7","author":"Z M Ruggeri","year":"1993","journal-title":"FASEB J"},{"issue":"21","key":"ref6","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood-2013-12-543074","article-title":"GpIb\u03b1-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice","volume":"123","author":"A Le Behot","year":"2014","journal-title":"Blood"},{"issue":"S 04","key":"ref7","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0049-3848(08)70028-8","article-title":"VWF attributes--impact on thrombus formation","volume":"122","author":"A J Reininger","year":"2008","journal-title":"Thromb Res"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1160\/TH05-07-0527","article-title":"Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years","volume":"95","author":"A D Blann","year":"2006","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","article-title":"von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes","volume":"117","author":"A O Spiel","year":"2008","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2019.09.003","article-title":"Von Willebrand factor antigen levels predict major adverse cardiovascular events in patients with carotid stenosis of the ICARAS study","volume":"290","author":"K D Kovacevic","year":"2019","journal-title":"Atherosclerosis"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1055\/s-0038-1648251","article-title":"Targeting von Willebrand factor in ischaemic stroke: focus on clinical evidence","volume":"118","author":"N Buchtele","year":"2018","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1160\/TH17-02-0087","article-title":"Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention","volume":"117","author":"J Siller-Matula","year":"2017","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/09537104.2015.1095874","article-title":"Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor","volume":"27","author":"J M Siller-Matula","year":"2016","journal-title":"Platelets"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1055\/s-0040-1702920","article-title":"Platelet inhibition in acute coronary syndrome and percutaneous coronary intervention: insights from the past and present","volume":"120","author":"D A Gorog","year":"2020","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cpt.1616","article-title":"Differential effects of ticagrelor with or without aspirin on platelet reactivity and coagulation activation: a randomized trial in healthy volunteers","volume":"107","author":"L Traby","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cpt.1492","article-title":"Effectiveness of antiplatelet drugs under therapeutic hypothermia: a comprehensive review","volume":"106","author":"C Eyileten","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/jcm7110442","article-title":"Cangrelor induces more potent platelet inhibition without increasing bleeding in resuscitated patients","volume":"7","author":"F Pr\u00fcller","year":"2018","journal-title":"J Clin Med"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1016\/j.ahj.2003.11.003","article-title":"Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial","volume":"147","author":"U Derhaschnig","year":"2004","journal-title":"Am Heart J"},{"issue":"13","key":"ref19","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1182\/blood-2002-11-3566","article-title":"Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb\/IIIa inhibitors and aspirin","volume":"102","author":"R A Reiter","year":"2003","journal-title":"Blood"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1042\/CS20120194","article-title":"Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial","volume":"123","author":"A O Spiel","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/TCRM.S152369","article-title":"Ticagrelor - toward more efficient platelet inhibition and beyond","volume":"14","author":"M J Kubisa","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"e102701","DOI":"10.1371\/journal.pone.0102701","article-title":"Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention","volume":"9","author":"J M Siller-Matula","year":"2014","journal-title":"PLoS One"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.thromres.2008.05.017","article-title":"ADAMTS-13 activity in the presence of elevated von Willebrand factor levels as a novel mechanism of residual platelet reactivity in high risk coronary patients on antiplatelet treatment","volume":"123","author":"R Marcucci","year":"2008","journal-title":"Thromb Res"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/jth.14755","article-title":"The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer","volume":"18","author":"S Zhu","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1038\/s41598-019-44673-7","article-title":"Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study","volume":"9","author":"M P Winter","year":"2019","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13102","article-title":"Platelet reactivity patterns in patients treated with dual antiplatelet therapy","author":"M P Winter","year":"2019","journal-title":"Eur J Clin Invest"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/09537100903085927","article-title":"The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction","volume":"20","author":"A O Spiel","year":"2009","journal-title":"Platelets"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.1985.tb07350.x","article-title":"An immunoradiometric assay for human factor VIII\/von Willebrand factor (VIII:vWF) using a monoclonal antibody that defines a functional epitope","volume":"59","author":"A H Goodall","year":"1985","journal-title":"Br J Haematol"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1055\/s-0038-1657727","article-title":"von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use","volume":"78","author":"P J Murdock","year":"1997","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1067\/mlc.2001.117406","article-title":"Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction","volume":"138","author":"B Jilma","year":"2001","journal-title":"J Lab Clin Med"},{"issue":"03","key":"ref31","first-page":"539","article-title":"A dose ranging phase I\/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura","volume":"106","author":"P Jilma-Stohlawetz","year":"2011","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1046\/j.1365-2141.2000.02473.x","article-title":"Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100","volume":"111","author":"M Homoncik","year":"2000","journal-title":"Br J Haematol"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/leu.2016.316","article-title":"Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib","volume":"31","author":"L Kazianka","year":"2017","journal-title":"Leukemia"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1160\/TH10-08-0530","article-title":"Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration. A randomised controlled trial","volume":"105","author":"A O Spiel","year":"2011","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref35","first-page":"781","article-title":"Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood","volume":"96","author":"O T\u00f3th","year":"2006","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref36","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.amjcard.2005.05.046","article-title":"In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score","volume":"96","author":"A T Yan","year":"2005","journal-title":"Am J Cardiol"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.amjcard.2004.03.024","article-title":"One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry)","volume":"94","author":"A T Yan","year":"2004","journal-title":"Am J Cardiol"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJM199907223410402","article-title":"Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators","volume":"341","author":"J S Hochman","year":"1999","journal-title":"N Engl J Med"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/jth.12194","article-title":"Reduced prevalence of arterial thrombosis in von Willebrand disease","volume":"11","author":"Y V Sanders","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1160\/TH10-08-0520","article-title":"Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura","volume":"105","author":"P Jilma-Stohlawetz","year":"2011","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijcard.2004.12.095","article-title":"Extensive coronary thrombosis in thrombotic-thrombocytopenic purpura","volume":"106","author":"D Hasper","year":"2006","journal-title":"Int J Cardiol"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/jth.14679","article-title":"Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study","volume":"18","author":"P Knoebl","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"S 05","key":"ref44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2516.2008.01848.x","article-title":"Function of von Willebrand factor in haemostasis and thrombosis","volume":"14","author":"A J Reininger","year":"2008","journal-title":"Haemophilia"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-0037-1616936","article-title":"Role of von Willebrand factor in vascular disease","volume":"29","author":"P Paulinska","year":"2009","journal-title":"Hamostaseologie"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/STROKEAHA.106.474569","article-title":"Predictive variables for mortality after acute ischemic stroke","volume":"38","author":"A M Carter","year":"2007","journal-title":"Stroke"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/01.ATV.10.3.449","article-title":"von Willebrand factor and occlusive arterial thrombosis. A study in normal and von Willebrand's disease pigs with diet-induced hypercholesterolemia and atherosclerosis","volume":"10","author":"T C Nichols","year":"1990","journal-title":"Arteriosclerosis"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/(SICI)1097-0304(199607)38:3<287::AID-CCD16>3.0.CO;2-E","article-title":"Acute myocardial infarction in a patient with von Willebrand disease","volume":"38","author":"C B Wong","year":"1996","journal-title":"Cathet Cardiovasc Diagn"},{"issue":"06","key":"ref49","first-page":"1455","article-title":"Are only haemophiliacs protected against ischemic heart disease?","volume":"92","author":"M Franchini","year":"2004","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/(SICI)1096-8652(199802)57:2<180::AID-AJH16>3.0.CO;2-G","article-title":"Successful thrombolysis for acute myocardial infarction in Type I von Willebrand's disease (vWD)","volume":"57","author":"G Fragasso","year":"1998","journal-title":"Am J Hematol"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.thromres.2012.02.050","article-title":"Outcomes of management of acute coronary syndrome in patients with congenital bleeding disorders: a single center experience and review of the literature","volume":"130","author":"M Y Lim","year":"2012","journal-title":"Thromb Res"},{"issue":"21","key":"ref52","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.V116.21.1406.1406","article-title":"Management strategies of stroke and acute coronary syndrome in von Willebrand disease and hemophilia: experience from a case series and a Swiss survey of frequencies","volume":"116","author":"S C Meyer","year":"2010","journal-title":"Blood"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00005792-198307000-00004","article-title":"Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases","volume":"62","author":"L T Goodnough","year":"1983","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"ref54","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1538-7836.2006.02239.x","article-title":"Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS","volume":"4","author":"I Fuchs","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1586\/erc.10.154","article-title":"Targeting von Willebrand factor and platelet glycoprotein Ib receptor","volume":"8","author":"C Firbas","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1160\/TH10-12-0804","article-title":"The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention","volume":"106","author":"J E van Loon","year":"2011","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12265-012-9422-3","article-title":"von Willebrand factor inhibition improves endothelial function in patients with stable angina","volume":"6","author":"O Muller","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/hq0102.101520","article-title":"Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys","volume":"22","author":"S Kageyama","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"ref59","first-page":"1391","article-title":"Critical role of von Willebrand factor and platelet interaction in venous thromboembolism","volume":"24","author":"M Takahashi","year":"2009","journal-title":"Histol Histopathol"},{"issue":"23","key":"ref60","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/CIRCULATIONAHA.107.724864","article-title":"First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers","volume":"116","author":"J C Gilbert","year":"2007","journal-title":"Circulation"},{"issue":"04","key":"ref61","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"S R Cataland","year":"2012","journal-title":"Am J Hematol"},{"issue":"03","key":"ref62","first-page":"563","article-title":"A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease","volume":"104","author":"B Jilma","year":"2010","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref63","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1160\/TH11-12-0889","article-title":"The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease","volume":"108","author":"P Jilma-Stohlawetz","year":"2012","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref64","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.111.616649","article-title":"The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial","volume":"42","author":"H S Markus","year":"2011","journal-title":"Stroke"},{"key":"ref65","first-page":"2020","article-title":"Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200","author":"S Zhu","journal-title":"J Thromb Haemost"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"461238","DOI":"10.1155\/2010\/461238","article-title":"Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies","volume":"2010","author":"T C Nichols","year":"2010","journal-title":"Thrombosis"},{"issue":"14","key":"ref67","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2015-03-632901","article-title":"Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice","volume":"126","author":"S Verhenne","year":"2015","journal-title":"Blood"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1713888.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T22:50:59Z","timestamp":1599000659000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1713888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":67,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2020,9,1]]},"published-print":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1713888","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,17]]}}}